Phase 3 Clinical Trial Comparing Iberdomide VS Lenalidomide as Maintenance Therapy Following Autologous Stem Cell Transplant in Participants with Newly Diagnosed Multiple Myeloma EXCALIBER-MAINTENANCE

What's the purpose of this trial?

The goal of this clinical trial is to learn more about the safety and efficacy of an investigational drug called Iberdomide when used as maintenance therapy, and to compare its safety and efficacy to Lenalidomide maintenance therapy. 

This trial is currently open and accepting patients.

What will happen during the trial?

Participation in this study will be randomized, which means the study team will randomly place participants into one of several different groups. This trial is open-label, which means that both researchers and participants will know which groups they are placed in, and which medications and doses they will be receiving.  

This trial is organized into two different parts, or stages. In Stage 1, researchers will compare the safety and efficacy of three different dose levels of investigational drug Iberdomide to the standard maintenance treatment of Lenalidomide. Participants in this stage will be randomly assigned into one of four different arms (or groups). Three arms (A1, A2, and A3) will receive one of three different doses of investigational drug Iberdomide. The fourth group will receive Lenalidomide. 

In Stage 2, researchers will compare the safety and efficacy of investigational Iberdomide (using the dose from Stage 1) versus Lenalidomide. Participants in this stage will be randomly assigned into one of two different arms (Arms A and B). Participants in either part of the study can continue to receive the treatment they were randomized to as long as their myeloma remains stable or improves, and they don’t experience important side effects.

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

• have measurable disease as defined by the trial criteria.
• have received 3-6 cycles of induction therapy, including a proteasome inhibitor and immunomodulatory agent (VTD [bortezomib, thalidomide, dexamethasone], RVd [lenalidomide, bortezomib, dexamethasone]) with or without a CD38 monoclonal antibody, or VCd (bortezomib, cyclophosphamide, dexamethasone) and followed by an autologous stem cell transplant. Participants are allowed to have received consolidation therapy after transplant.
• must be within 12 months from start of induction therapy, and have achieved at least a partial response after stem cell transplant.
• do not have known myeloma involvement in the central nervous system.
• have adequate bone marrow, kidney, and liver function.

Additional Trial Information

Phase 3

Enrollment: 1,216 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.


Rocky Mountain Cancer Centers (Aurora) Aurora

Aurora, CO

Open and Accepting

University of Colorado Health - Poudre Valley Hospital Poudre Valley Hospital

Fort Collins, CO

Not Yet Accepting


Mayo Clinic (Jacksonville)

Jacksonville, FL

Not Yet Accepting

Moffitt Cancer Center Magnolia Campus

Tampa, FL

Not Yet Accepting

Cleveland Clinic Florida

Weston, FL

Open and Accepting


Winship Cancer Institute Emory University

Atlanta, GA

Not Yet Accepting

University Cancer and Blood Center

Athens, GA

Open and Accepting

Augusta University Medical Center

Augusta, GA

Not Yet Accepting


University of Chicago Medicine Comprehensive Cancer Center

Chicago, IL

Not Yet Accepting


University of Kansas Cancer Center

Kansas City, KS

Not Yet Accepting


Maryland Oncology Hematology (Clinton)

Clinton, MD

Open and Accepting


University of Massachusetts Medical School

Worcester, MA

Not Yet Accepting


University of Michigan Comprehensive Cancer Center Rogel Cancer Center

Ann Arbor, MI

Not Yet Accepting

Henry Ford Hospital

Detroit, MI

Not Yet Accepting


Hattiesburg Clinic

Hattiesburg, MS

Open and Accepting


HCA Midwest Health

Kansas City, MO

Open and Accepting

New Hampshire

Dartmouth-Hitchcock Medical Center Norris Cotton Cancer Center

Lebanon, NH

Not Yet Accepting

New Jersey

Morristown Medical Center Atlantic Health System

Morristown, NJ

Not Yet Accepting

New York

Memorial Sloan Kettering Cancer Center

New York, NY

Not Yet Accepting

NYU Langone - Long Island

Mineola, NY

Not Yet Accepting

North Carolina

Novant Health Presbyterian Medical Center Novant Health

Charlotte, NC

Open and Accepting

Novant Health Forsyth Cancer Institute - Bethesda Court

Winston-Salem, NC

Not Yet Accepting


Oncology Hematology Care Inc. (Kenwood)

Cincinnati, OH

Open and Accepting

Cleveland Clinic - Taussig Cancer Center Taussig Cancer Institute

Cleveland, OH

Not Yet Accepting

Toledo Clinic Cancer Centers - Toledo

Toledo, OH

Open and Accepting


Willamette Valley Cancer Institute (Eugene)

Eugene, OR

Open and Accepting


Thomas Jefferson University Hospital

Philadelphia, PA

Open and Accepting

Fox Chase Cancer Center Temple Health

Philadelphia, PA

Not Yet Accepting

UPMC Hillman Cancer Center University of Pittsburgh Medical Center (UPMC)

Pittsburgh, PA

Not Yet Accepting


Sarah Cannon Tennessee Oncology- Nashville (24th Ave) Centennial Clinic

Nashville, TN

Open and Accepting


Baylor Charles A. Sammons Cancer Center Baylor Scott & White Health

Dallas, TX

Open and Accepting

MD Anderson Cancer Center The University of Texas

Houston, TX

Not Yet Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

Learn more about how we work with trial sponsors